1. Home
  2. HCAT vs MOLN Comparison

HCAT vs MOLN Comparison

Compare HCAT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Health Catalyst Inc

HCAT

Health Catalyst Inc

HOLD

Current Price

$1.04

Market Cap

121.7M

Sector

Technology

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.10

Market Cap

144.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCAT
MOLN
Founded
2008
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
121.7M
144.0M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
HCAT
MOLN
Price
$1.04
$4.10
Analyst Decision
Hold
Buy
Analyst Count
10
2
Target Price
$2.53
$8.38
AVG Volume (30 Days)
764.1K
3.6K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$311,136,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$318.52
P/E Ratio
N/A
N/A
Revenue Growth
1.48
N/A
52 Week Low
$1.04
$3.36
52 Week High
$5.06
$5.36

Technical Indicators

Market Signals
Indicator
HCAT
MOLN
Relative Strength Index (RSI) 30.06 40.81
Support Level N/A $3.53
Resistance Level $2.41 $4.51
Average True Range (ATR) 0.10 0.17
MACD 0.01 -0.04
Stochastic Oscillator 0.00 29.63

Price Performance

Historical Comparison
HCAT
MOLN

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: